Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 6/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.68 |
| ▸ | MAOA | P21397 | 11/20 | 0.67 |
| ▸ | MAOB | P27338 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24143791 | 1.00 | CALML3 (0.76) | CALML3CYP2C19CYP3A4MAOAMAOB | |
| SCHEMBL18786542 | 0.91 | CALML3 (0.64) | CALML3CYP2C19CYP3A4MAOAMAOB | |
| SCHEMBL18786484 | 0.91 | CALML3 (0.64) | CALML3CYP2C19CYP3A4MAOAMAOB | |
| SCHEMBL18787358 | 0.90 | CALML3 (0.62) | CALML3CYP2C19CYP3A4MAOAMAOB | |
| SCHEMBL24125180 | 0.90 | CALML3 (0.62) | CALML3CYP2C19CYP3A4MAOAMAOB | |
| SCHEMBL14839459 | 0.89 | CALML3 (0.73) | CALML3CYP2C19CYP3A4MAOAMAOB | |
| SCHEMBL29432576 | 0.87 | CALML3 (0.77) | CALML3CYP2C19CYP3A4MAOAMAOB | |
| SCHEMBL22245049 | 0.87 | CALML3 (0.77) | CALML3CYP2C19CYP3A4MAOAMAOB | |
| SCHEMBL3323279 | 0.87 | CALML3 (0.80) | CALML3CYP2C19CYP3A4MAOAMAOB | |
| SCHEMBL3323276 | 0.87 | CALML3 (0.80) | CALML3CYP2C19CYP3A4MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023122759-A2 | OXAZOLIDINONE LIPOSOME COMPOSITIONS | AKAGERA MEDICINES, INC. (US) | 2023-06-29 | — | — | WO | disclosed |